Order Article Reprints

Ahmed-Belkacem A, Redjoul R, Brillet R, Ahnou N, Leclerc M, López-Molina DS, Soulier A, Gourgeon A, Rodriguez C, Maury S, et al. Third Early “Booster” Dose Strategy in France of bnt162b2 SARS-CoV-2 Vaccine in Allogeneic Hematopoietic Stem Cell Transplant Recipients Enhances Neutralizing Antibody Responses. Viruses. 2022; 14(9):1928. https://doi.org/10.3390/v14091928

Ahmed-Belkacem, Abdelhakim, Rabah Redjoul, Rozenn Brillet, Nazim Ahnou, Mathieu Leclerc, Dennis Salomón López-Molina, Alexandre Soulier, Aurélie Gourgeon, Christophe Rodriguez, Sébastien Maury, and et al. 2022. "Third Early “Booster” Dose Strategy in France of bnt162b2 SARS-CoV-2 Vaccine in Allogeneic Hematopoietic Stem Cell Transplant Recipients Enhances Neutralizing Antibody Responses" Viruses 14, no. 9: 1928. https://doi.org/10.3390/v14091928

Ahmed-Belkacem, A., Redjoul, R., Brillet, R., Ahnou, N., Leclerc, M., López-Molina, D. S., Soulier, A., Gourgeon, A., Rodriguez, C., Maury, S., Pawlotsky, J.-M., & Fourati, S. (2022). Third Early “Booster” Dose Strategy in France of bnt162b2 SARS-CoV-2 Vaccine in Allogeneic Hematopoietic Stem Cell Transplant Recipients Enhances Neutralizing Antibody Responses. Viruses, 14(9), 1928. https://doi.org/10.3390/v14091928